Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-23T01:39:32.106Z Has data issue: false hasContentIssue false
  • English
  • Français

Ziprasidone in the treatment of Parkinson’s disease psychosis

Published online by Cambridge University Press:  16 April 2020

I-Shin Shiah ,
Chun-Lung Lin ,
Wei-Chung Mao  and
Sy-Ueng Luu
I-Shin Shiah*
Affiliation:
Department of Psychiatry, Tri-Service General Hospital, No. 325, Sec. 2, Cheng-Gung Road, Neihu District, Taipei114, Taiwan, ROC National Defense Medical Center, Taipei, Taiwan, ROC
Chun-Lung Lin
Affiliation:
Department of Psychiatry, Tri-Service General Hospital, No. 325, Sec. 2, Cheng-Gung Road, Neihu District, Taipei114, Taiwan, ROC
Wei-Chung Mao
Affiliation:
Department of Psychiatry, Tri-Service General Hospital, No. 325, Sec. 2, Cheng-Gung Road, Neihu District, Taipei114, Taiwan, ROC
Sy-Ueng Luu
Affiliation:
National Defense Medical Center, Taipei, Taiwan, ROC Department of Psychiatry, Hualien Armed Forced General Hospital, Hualien, Taiwan, ROC
*
*Corresponding author. Tel.: +11 886 2 8792 7431; fax: +11 886 2 8791 2161. E-mail address: [email protected] (I.-S. Shiah).
Get access

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

l-DopaParkinson’s diseasePsychosisZiprasidone
Type
Case-report
Information
European Psychiatry , Volume 21 , Issue 8 , December 2006 , pp. 578 - 579
Copyright
Copyright © Elsevier Masson SAS 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Abbreviations: DA, dopamine; DBS, deep brain stimulation; EPS, extrapyramidal side effects; 5-HT, serotonin; MMSE, mini-mental state examination; MRI, magnetic resolution imaging; PD, Parkinson's disease; UPDRS, unified Parkinson disease rating scale.

References

Connemann, B.J., Schonfeldt-Lecuona, C.Ziprasidone in Parkinson’s disease psychosis Can. J. Psychiatry 2004; 49(1): 73.CrossRefGoogle ScholarPubMed
Cummings, J.L.Managing psychosis in patients with Parkinson’s disease N. Engl. J. Med. 340(10)1999 801–803.CrossRefGoogle ScholarPubMed
Juncos, J.L.Management of psychotic aspects of Parkinson’s disease J. Clin. Psychiatry 60(Suppl 8)1999 42–53.Google ScholarPubMed
Juncos, J.L., R, V.J., Evatt, M.L., Jewart, R.D., Wood, C.D., Potter, L.S.et al.Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease Mov. Disord. 19(1)2004 29–35.CrossRefGoogle ScholarPubMed
Morgante, L., Epifanio, A., Spina, E., Zappia, M., Di Rosa, A.E., Marconi, R.et al.Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis Clin. Neuropharmacol. 27(4)2004 153–156.CrossRefGoogle ScholarPubMed
Oechsner, M., Korchounov, A.Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson’s disease? Hum. Psychopharmacol. 20(3)2005 203–205.CrossRefGoogle ScholarPubMed
Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease N. Engl. J. Med. 340(10)1999 757–763.CrossRefGoogle Scholar
Pollak, P., Tison, F., Rascol, O., Destee, A., Pere, J.J., Senard, J.M.et al.Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up J. Neurol. Neurosurg. Psychiatry 75(5)2004 689–695.CrossRefGoogle ScholarPubMed
Targum, S.D., Abbott, J.L.Efficacy of quetiapine in Parkinson’s patients with psychosis J. Clin. Psychopharmacol. 20(1)2000 54–60.CrossRefGoogle ScholarPubMed
The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson’s disease Lancet 353(9169)1999 2041–2042.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.